Neos Therapeutics hopes novel drug delivery will help newly approved Adzenys XR-ODT outcompete generic rivals in the ADHD drug market. The tablet disintegrates in the mouth and does not need to be swallowed. "This first ever FDA approval of a product using our proprietary extended-release, orally disintegrating tablet technology is an important milestone for Neos," CEO Vipin Garg said in a statement. "We believe that Adzenys XR-ODT will provide an important innovation for treatment in the ADHD market, and we intend to begin educating healthcare providers about our exciting new product immediately." The amphetamine-based tablet is similar to Shire's ($SHPG) Adderall but boasts enhanced drug delivery. More from FierceBiotech